Costs of relapsed diffuse large B-cell lymphoma among Medicare patients

Area of Science:

• Oncology
• Health Economics
• Clinical Research

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a significant health concern with substantial associated healthcare expenditures.
• The economic impact of treatment failure, specifically relapse, following first-line therapy for DLBCL remains incompletely understood.

Purpose of the Study:

• To compare healthcare expenditures between patients with DLBCL who relapsed after first-line therapy and those who did not.
• To identify specific drivers of increased healthcare costs in the relapsed DLBCL population.

Main Methods:

• Analysis of 100% Medicare claims data for patients diagnosed with DLBCL and treated with first-line therapy between January 2010 and June 2014.
• Comparison of monthly healthcare costs between a relapse cohort (received second-line immunochemotherapy) and a non-relapse cohort (did not receive second-line therapy).
• Propensity score matching was employed to control for confounding variables between the two cohorts.

Main Results:

• The relapse cohort incurred substantially higher monthly healthcare costs ($6998) compared to the non-relapse cohort ($3314) (p < .001).
• Inpatient costs were significantly higher in the relapsed group ($2548/month vs $1943/month; p < .001).
• Outpatient office visit costs were markedly higher in the relapsed cohort ($3581/month vs $753/month; p < .001).

Conclusions:

• Older adults with relapsed DLBCL experience significantly elevated medical costs, primarily driven by inpatient and outpatient services.
• These findings underscore the economic benefits of improving first-line DLBCL treatments to minimize relapse rates and associated healthcare expenditures.